Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02130284 · ClinicalTrials.gov registry record · NA

In Clinic Evaluation of the PLGM Feature

A NA study of Type 1 Diabetes, sponsored by Medtronic Diabetes.

Completed
Registry status
NA
Development phase
80
Enrollment target
8
Study locations

NCT02130284: Completed NA study of Type 1 Diabetes, sponsored by Medtronic Diabetes.

NCT02130284 is a NA study of Type 1 Diabetes that has completed, run by Medtronic Diabetes. The registered enrollment target is 80 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (90% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02130284, a NA study of Type 1 Diabetes, has completed, sponsored by Medtronic Diabetes.

COMPLETED
Registry status
NA
Development phase
80 participants
Enrollment target
8
Study locations

Study Summary

This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.

Primary Outcome

Evaluation of incidence of SAE during in-clinic procedures

Conditions Studied

Interventions

  • DEVICE Predictive Low Glucose Management Feature in Insulin pump

Study Locations (8)

California

  • AMCR Institute, Inc. - Escondido
  • Stanford University Department of Pediatric Endocrinology - Stanford
  • Diablo Clinical Research - Walnut Creek

Colorado

  • Barbara Davis Center of Childhood Diabetes - Denver

Connecticut

  • Yale University Diabetes Research Program - New Haven

Georgia

  • Atlanta Diabetes Associates - Atlanta

Virginia

  • University of Virgina - Charlottesville

Washington

  • Rainier Clinical Research - Renton

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2014-10
Est. Completion 2015-09
Phase NA
Medtronic Diabetes

9 total trials

What the finished NCT02130284 record still lists

NCT02130284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Predictive Low Glucose Management Feature in Insulin pump is the first listed.

NCT02130284 lists 8 locations in 6 states (California, Colorado, Connecticut).

Frequently Asked Questions

What is clinical trial NCT02130284 about?

NCT02130284 is a clinical study titled "In Clinic Evaluation of the PLGM Feature". This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.

What is the current status of trial NCT02130284?

This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2014-10. Estimated completion is 2015-09.

What conditions does trial NCT02130284 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT02130284?

The interventions under investigation include: Predictive Low Glucose Management Feature in Insulin pump (DEVICE).

Who is sponsoring clinical trial NCT02130284?

This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02130284 being conducted?

This trial has 8 study locations across California, Colorado, Connecticut, Georgia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02130284's enrollment target sits among peer trials

80 63rd of 198 higher than 133 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02130284, the US trial registry maintained by the National Library of Medicine. NCT02130284 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.